ES2091738T1 - Formulados farmaceuticos de cefaclor. - Google Patents

Formulados farmaceuticos de cefaclor.

Info

Publication number
ES2091738T1
ES2091738T1 ES95304976T ES95304976T ES2091738T1 ES 2091738 T1 ES2091738 T1 ES 2091738T1 ES 95304976 T ES95304976 T ES 95304976T ES 95304976 T ES95304976 T ES 95304976T ES 2091738 T1 ES2091738 T1 ES 2091738T1
Authority
ES
Spain
Prior art keywords
cefaclor
pharmaceutical
formulates
manufacture
dispersible tablets
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
ES95304976T
Other languages
English (en)
Other versions
ES2091738T3 (es
Inventor
Mendizabal Flavia Arce
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Lilly SA
Original Assignee
Lilly SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly SA filed Critical Lilly SA
Publication of ES2091738T1 publication Critical patent/ES2091738T1/es
Application granted granted Critical
Publication of ES2091738T3 publication Critical patent/ES2091738T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/545—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nutrition Science (AREA)
  • Communicable Diseases (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Oncology (AREA)
  • Physiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Cephalosporin Compounds (AREA)

Abstract

FORMULACIONES FARMACEUTICAS DE CEFACLOR, ADECUADAS PARA LA FABRICACION POR COMPRESION DIRECTA DE COMPRIMIDOS DISPERSABLES, QUE CONTIENE EL ANTIBIOTICO CEFACLOR EN UNA CANTIDAD ENTRE UN 35% Y UN 50% EN PESO DEL PESO TOTAL DE LA FORMULACION, JUNTO CON LOS EXCIPIENTES Y COADYUVANTES ADECUADOS SELECCIONADOS ENTRE DESINTEGRADORES, DILUYENTES, LUBRICANTES, ANTIADHERENTES, EDULCORANTES, FRAGANCIAS Y, OPCIONALMENTE, AROMATIZANTES, OPACIFICADORES Y COLORANTES. DICHAS FORMULACIONES SON ADECUADAS PARA LA FABRICACION DE COMPRIMIDOS DISPERSABLES QUE SE DESINTEGRAN EN MENOS DE TRES MINUTOS EN AGUA A UNA TEMPERATURA ENTRE 19 (GRADOS) Y 21 (GRADOS) C, Y SON ADECUADAS PARA EL TRATAMIENTO DE LAS INFECCIONES PROVOCADAS POR AQUELLAS ESPECIES DE BACTERIAS SENSIBLES AL CEFACLOR.
ES95304976T 1994-12-13 1995-07-17 Formulados farmaceuticos que contienen cefaclor. Expired - Lifetime ES2091738T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
ES09402530A ES2079327B1 (es) 1994-12-13 1994-12-13 Formulaciones farmaceuticas de cefaclor.

Publications (2)

Publication Number Publication Date
ES2091738T1 true ES2091738T1 (es) 1996-11-16
ES2091738T3 ES2091738T3 (es) 2001-08-16

Family

ID=8288235

Family Applications (2)

Application Number Title Priority Date Filing Date
ES09402530A Expired - Lifetime ES2079327B1 (es) 1994-12-13 1994-12-13 Formulaciones farmaceuticas de cefaclor.
ES95304976T Expired - Lifetime ES2091738T3 (es) 1994-12-13 1995-07-17 Formulados farmaceuticos que contienen cefaclor.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
ES09402530A Expired - Lifetime ES2079327B1 (es) 1994-12-13 1994-12-13 Formulaciones farmaceuticas de cefaclor.

Country Status (32)

Country Link
US (1) US5861141A (es)
EP (3) EP0716852B1 (es)
JP (1) JPH08208484A (es)
KR (1) KR100350565B1 (es)
CN (1) CN1136852C (es)
AT (1) ATE201984T1 (es)
AU (1) AU702585B2 (es)
BR (1) BR9504573A (es)
CA (1) CA2158511A1 (es)
CO (1) CO4410176A1 (es)
CZ (1) CZ287248B6 (es)
DE (2) DE69521275T2 (es)
DK (1) DK0716852T3 (es)
ES (2) ES2079327B1 (es)
FI (1) FI953887A (es)
GR (2) GR960300062T1 (es)
HK (1) HK1012574A1 (es)
HU (1) HUT73792A (es)
IL (1) IL114642A (es)
MY (1) MY114687A (es)
NO (1) NO309925B1 (es)
NZ (1) NZ272611A (es)
PE (1) PE5196A1 (es)
PL (1) PL181437B1 (es)
PT (1) PT716852E (es)
RU (1) RU2150276C1 (es)
SI (1) SI0716852T1 (es)
TR (1) TR199501165A1 (es)
TW (1) TW492875B (es)
UA (1) UA34479C2 (es)
YU (1) YU60795A (es)
ZA (1) ZA956411B (es)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2231369T3 (es) * 1996-02-29 2005-05-16 Fujisawa Pharmaceutical Co., Ltd. Granulo de disgregacion rapida de un edulcorante sintetico que contiene acido silicico y/o dioxido de silicio.
AU1150799A (en) * 1997-10-10 1999-05-03 Yamanouchi Europe B.V. Oral compositions containing a cephalosporin antibiotic
PL197077B1 (pl) * 1998-12-01 2008-02-29 Reddys Lab Inc Dr Kompozycja farmaceutyczna zawierająca 5-[[4-[3-metylo-4-okso-3,4-dihydro-2-chinazolinylo]metoksy]fenylometylo]-tiazolidyno-2,4-dion lub jego sól dopuszczalną do stosowania w farmacji i sposób jej wytwarzania
DE10005017A1 (de) * 2000-02-04 2001-08-09 Cognis Deutschland Gmbh Duftstofftabletten
JP2004531537A (ja) * 2001-05-01 2004-10-14 ファイザー・プロダクツ・インク 一様な薬剤分布と効力を有する低用量製薬組成物の製造方法
US7151432B2 (en) 2001-09-19 2006-12-19 Immersion Corporation Circuit and method for a switch matrix and switch sensing
GB0209265D0 (en) 2002-04-23 2002-06-05 Novartis Ag Organic compounds
TW200404550A (en) * 2002-07-08 2004-04-01 Sankyo Co Cepharospolin formulation for oral use
JP4526247B2 (ja) * 2002-07-08 2010-08-18 第一三共株式会社 経口用セファロスポリン製剤
US8968768B2 (en) * 2004-03-29 2015-03-03 Wyeth Llc Phytosterol nutritional supplements
CA2560595C (en) 2004-03-29 2013-01-22 Wyeth Multi-vitamin and mineral nutritional supplements
US9198862B2 (en) 2005-07-22 2015-12-01 Rubicon Research Private Limited Dispersible tablet composition
CA2618977C (en) 2005-08-10 2014-10-21 Shionogi & Co., Ltd. Orally disintegratable tablet
CN102579455B (zh) * 2012-03-19 2014-02-19 迪沙药业集团有限公司 一种稳定的头孢克洛咀嚼组合物
WO2017045742A1 (de) * 2015-09-14 2017-03-23 Merck Patent Gmbh Formulierung mit kontrollierter, verzögerter wirkstoffreisetzung
CN113750066B (zh) * 2021-10-12 2022-12-02 上海金城素智药业有限公司 一种具有临床优势的头孢克洛制剂及其制备方法和应用

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2259646C2 (de) * 1972-12-06 1984-11-22 Hoechst Ag, 6230 Frankfurt Hochdosierte Tabletten von Cephalosporin-Derivaten sowie Verfahren zu ihrer Herstellung
YU36970B (en) 1973-02-23 1984-08-31 Lilly Co Eli Process for obtaining 7-(amino)-acylamido-3-halocephalosporins
US3925372A (en) 1973-02-23 1975-12-09 Lilly Co Eli Alpha-aminoacyl-3-halo cephalosporins
US4143129A (en) * 1975-10-11 1979-03-06 Lilly Industries Limited Cephalexin tablets
GB2066662B (en) * 1979-12-21 1984-02-15 Glaxo Group Ltd Cephalexin powder compositions containing silicon dioxide
NZ198241A (en) * 1980-09-27 1983-12-16 Beecham Group Ltd Tablet containing amoxycillin and potassium clavulanate
JPS601128A (ja) * 1983-06-15 1985-01-07 Shionogi & Co Ltd 作用持続型セフアクロル製剤
EP0181966A1 (en) * 1984-11-13 1986-05-28 Gist-Brocades N.V. Compression-coated dispersible tablets
DE3887179T2 (de) * 1987-03-02 1994-06-16 Brocades Pharma Bv Pharmazeutische Zusammensetzung, pharmazeutisches Granulat und Verfahren zu ihrer Herstellung.
EP0319074B1 (en) * 1987-11-30 1992-01-29 Brocades Pharma B.V. Pharmaceutical composition and process for its preparation
DE3838431A1 (de) * 1988-11-12 1990-05-17 Bayer Ag Ibuprofen-brausezubereitungen
GB9009473D0 (en) * 1990-04-27 1990-06-20 Beecham Group Plc Pharmaceutical formulation
FR2669221B1 (fr) * 1990-11-15 1993-01-15 Rhone Poulenc Sante Procede de preparation par compression directe de comprimes de derives de l'acide cephalosporanique.
EP0487774B1 (en) * 1990-11-29 1994-10-26 Wei Ming Pharmaceutical Mfg. Co. Ltd. A direct tabletting auxiliary
EP0522128B1 (en) * 1991-01-30 1996-01-17 The Wellcome Foundation Limited Water-dispersible tablets
GB9109862D0 (en) * 1991-05-08 1991-07-03 Beecham Lab Sa Pharmaceutical formulations
IT1251999B (it) * 1991-11-11 1995-05-27 Opos Biochimica Srl Forma cristallina di un antibiotico cefalosporinico
PL171630B1 (pl) * 1992-04-30 1997-05-30 Schering Corp Preparat hydratowanego ceftibutenu i sposób wytwarzania preparatu hydratowanego ceftibutenu PL PL PL PL PL PL PL PL PL
US5503846A (en) * 1993-03-17 1996-04-02 Cima Labs, Inc. Base coated acid particles and effervescent formulation incorporating same
US5506248A (en) * 1993-08-02 1996-04-09 Bristol-Myers Squibb Company Pharmaceutical compositions having good dissolution properties
US5616344A (en) * 1994-06-14 1997-04-01 Fuisz Technologies Ltd. Apparatus and process for strengthening low density compression dosage units and product therefrom
US5895664A (en) * 1993-09-10 1999-04-20 Fuisz Technologies Ltd. Process for forming quickly dispersing comestible unit and product therefrom
US5622719A (en) * 1993-09-10 1997-04-22 Fuisz Technologies Ltd. Process and apparatus for making rapidly dissolving dosage units and product therefrom
US5595761A (en) * 1994-01-27 1997-01-21 The Board Of Regents Of The University Of Oklahoma Particulate support matrix for making a rapidly dissolving tablet
US5605889A (en) * 1994-04-29 1997-02-25 Pfizer Inc. Method of administering azithromycin

Also Published As

Publication number Publication date
GR960300062T1 (en) 1996-11-30
CN1136852C (zh) 2004-02-04
DE69521275D1 (de) 2001-07-19
JPH08208484A (ja) 1996-08-13
PE5196A1 (es) 1996-03-26
MY114687A (en) 2002-12-31
NZ272611A (en) 1997-08-22
EP0716852B1 (en) 2001-06-13
FI953887A (fi) 1996-06-14
CZ287248B6 (en) 2000-10-11
EP1086690A2 (en) 2001-03-28
HK1012574A1 (en) 1999-08-06
HUT73792A (en) 1996-09-30
DK0716852T3 (da) 2001-09-03
IL114642A (en) 1999-07-14
EP1086689A3 (en) 2001-07-11
UA34479C2 (uk) 2001-03-15
ES2091738T3 (es) 2001-08-16
ES2079327A1 (es) 1996-01-01
CZ199895A3 (en) 1996-07-17
EP1086690A3 (en) 2001-07-11
SI0716852T1 (en) 2001-12-31
ATE201984T1 (de) 2001-06-15
KR960021026A (ko) 1996-07-18
CN1130506A (zh) 1996-09-11
YU60795A (sh) 1998-07-10
NO953192L (no) 1996-06-14
EP0716852A1 (en) 1996-06-19
HU9502160D0 (en) 1995-09-28
PL181437B1 (pl) 2001-07-31
CA2158511A1 (en) 1996-06-14
US5861141A (en) 1999-01-19
DE69521275T2 (de) 2001-10-31
ES2079327B1 (es) 1996-08-01
FI953887A0 (fi) 1995-08-17
PL309863A1 (en) 1996-06-24
AU702585B2 (en) 1999-02-25
BR9504573A (pt) 1997-02-25
IL114642A0 (en) 1995-11-27
NO953192D0 (no) 1995-08-14
TR199501165A1 (tr) 1996-10-21
RU2150276C1 (ru) 2000-06-10
ZA956411B (en) 1996-03-11
KR100350565B1 (ko) 2003-02-05
AU2509495A (en) 1996-06-20
EP1086689A2 (en) 2001-03-28
DE716852T1 (de) 1997-04-03
CO4410176A1 (es) 1997-01-09
GR3036503T3 (en) 2001-11-30
TW492875B (en) 2002-07-01
NO309925B1 (no) 2001-04-23
PT716852E (pt) 2001-09-28

Similar Documents

Publication Publication Date Title
ES2091738T1 (es) Formulados farmaceuticos de cefaclor.
ES2091737T1 (es) Formulados farmaceuticos de fluoxetina.
TW262461B (es)
DE69905368D1 (en) Oxydiertes thymosin beta 4

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 716852

Country of ref document: ES